ADC Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- ADC Biotechnology's estimated annual revenue is currently $2.3M per year.
- ADC Biotechnology's estimated revenue per employee is $155,000
Employee Data
- ADC Biotechnology has 15 Employees.
- ADC Biotechnology grew their employee count by -17% last year.
ADC Biotechnology's People
| Name | Title | Email/Phone |
|---|
ADC Biotechnology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is ADC Biotechnology?
ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release' technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release' platform drives value through better products delivered with greater efficiency. In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing. For more information on our services and Lock Release please visit www.adcbio.com
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ADC Biotechnology News
Sterling's Deeside facility was part of its acquisition of ADC Biotechnology, which broadened the company's small molecule drug development...
Other Companies in Deeside
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.2M | 56 | 22% | N/A |
#2 | $12.3M | 56 | 2% | N/A |
#3 | $12.2M | 79 | 4% | N/A |
#4 | $8.6M | 86 | -29% | N/A |
#5 | $28.7M | 99 | 6% | N/A |